FIRST AMENDED EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This FIRST AMENDED EMPLOYMENT AGREEMENT dated March 29, 2022, and effective as of January 31, 2022, (this “Agreement”) between Virpax Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Jeffrey Gudin, MD (the “Executive”).
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. AMENDED & RESTATED COLLABORATION AND LICENSE AGREEMENT BETWEEN NANOMERICS Ltd AND VIRPAX PHARMACEUTICALS, INC.Collaboration and License Agreement • March 31st, 2022 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended & Restated Collaboration and License Agreement (this “Agreement”) is made effective as of the 9th day of March 2022 (the “New Effective Date”), by and between
FIRST AMENDED EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This FIRST AMENDED EMPLOYMENT AGREEMENT dated March 29, 2022, and effective as of January 31, 2022, (this “Agreement”) between Virpax Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Christopher Chipman (the “Executive”).
FIRST AMENDED EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This FIRST AMENDED EMPLOYMENT AGREEMENT dated March 29, 2022, and effective as of January 31, 2022 (this “Agreement”) between Virpax Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Anthony P. Mack (the “Executive”).
